Our study met the primary endpoint, showing antitumour activity (clinical complete response rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC, enabling personalised INRT, and supporting phase 3 trials of this treatment in patients with stage 3 SCAC.
[Articles] Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
The Lancet Oncology | | Stefano Kim, Jihane Boustani, Soledad Iseas, Dewi Vernerey, Ludovic Evesque, Laurent Quero, Francois Ghiringhelli, Clélia Coutzac, Olivier Bouché, Benoist Chibaudel, Chloé Vernet, Angélique Vienot, David Tougeron, Thierry Nguyen, Magali Rebucci-Peixoto, Aurélia Meurisse, Sarah Chennoufi, Christophe Maritaz, Christophe Borg, INTERACT-ION Study Team
Topics: blood-cancer, cervical-cancer, chemotherapy, radiation, clinical-trials, research